We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+24.47%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.91B
AUM Growth
+$85.7M
Cap. Flow
-$231M
Cap. Flow %
-12.11%
Top 10 Hldgs %
76.45%
Holding
46
New
3
Increased
22
Reduced
1
Closed
5

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$60.4M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$33.5M
3
EHTH icon
eHealth
EHTH
+$23.3M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$23.3M
5
RVNC
Revance Therapeutics, Inc.
RVNC
+$17.6M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$413M
2
AMAG
AMAG Pharmaceuticals
AMAG
+$28.2M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$1.55M
4
EOLS icon
Evolus
EOLS
+$1.04M
5
AIMT
Aimmune Therapeutics
AIMT
+$682K

Sector Composition

Rank Sector Weight
1 Healthcare 97.42%
2 Financials 2.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
26
DELISTED
Zogenix, Inc.
ZGNX
$4.29M 0.23%
214,700
+51,100
+31% +$1.04M
ATNX
27
DELISTED
Athenex, Inc. Common Stock
ATNX
$3.52M 0.18%
15,910
+3,070
+24% +$756K
RIGL icon
28
Rigel Pharmaceuticals
RIGL
$782M
$3.49M 0.18%
99,816
-18,593
-16% -$538K
DNTH icon
29
Dianthus Therapeutics
DNTH
$6.29B
$3.35M 0.18%
26,694
+5,213
+24% +$591K
ALKS icon
30
Alkermes
ALKS
$8.44B
$3M 0.16%
+150,598
New +$2.76M
KZR
31
DELISTED
Kezar Life Sciences
KZR
$2.86M 0.15%
54,821
+5,889
+12% +$328K
CYTK icon
32
Cytokinetics
CYTK
$10.5B
$2.57M 0.13%
123,686
– –
TCMD icon
33
Tactile Systems Technology
TCMD
$555M
$1.22M 0.06%
+27,100
New +$1.08M
ALDX icon
34
Aldeyra Therapeutics
ALDX
$91.7M
$1.1M 0.06%
160,800
+42,800
+36% +$301K
ALIM
35
DELISTED
Alimera Sciences
ALIM
$848K 0.04%
200,919
– –
APRE icon
36
Aprea Therapeutics
APRE
$8.46M
$634K 0.03%
6,439
+449
+7% +$214K
URGN icon
37
UroGen Pharma
URGN
$2.39B
$441K 0.02%
24,500
– –
MRNS
38
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$382K 0.02%
31,330
– –
ACGN
39
DELISTED
Aceragen Inc
ACGN
$283K 0.01%
4,537
– –
VIRX
40
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$231K 0.01%
33,213
– –
NERV icon
41
Minerva Neurosciences
NERV
$187M
$85K ﹤0.01%
4,540
– –
EOLS icon
42
Evolus
EOLS
$536M
– –
-265,700
Closed -$1.04M
TCDA
43
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-170,800
Closed -$1.55M
AMAG
44
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-3,003,875
Closed -$28.2M
IMMU
45
DELISTED
Immunomedics Inc
IMMU
– –
-4,852,383
Closed -$413M
AIMT
46
DELISTED
Aimmune Therapeutics
AIMT
– –
-19,800
Closed -$682K
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q4 2020 Portfolio in Review

As of Q4 2020, Palo Alto Investors held 46 positions worth $1.91B, up 4.7% from $1.82B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Palo Alto Investors withdrew a net $231M in Q4 2020, closing 5 positions and reducing 1 holding. Its most notable exit was Immunomedics Inc, an estimated $413M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 74% a quarter earlier, followed by Financials.

Against the trend, Palo Alto Investors opened a new position in Biogen worth $57.4M.

  • Palo Alto Investors's largest Q4 2020 buy was Biogen: 234,300 shares worth $57.4M.
  • Palo Alto Investors added most to BioMarin Pharmaceuticals in Q4 2020, an estimated $33.5M increase.
  • Palo Alto Investors's biggest Q4 2020 reduction was Rigel Pharmaceuticals, cutting an estimated $538K.
  • Palo Alto Investors fully exited Immunomedics Inc in Q4 2020, selling an estimated $413M.
  • Palo Alto Investors's ten largest holdings make up 76% of its $1.91B portfolio in Q4 2020.
  • Palo Alto Investors opened 3 new positions and closed 5 in Q4 2020.
  • Palo Alto Investors's portfolio value rose 4.7% quarter-over-quarter to $1.91B.

Based on Palo Alto Investors's 13F filing for Q4 2020, filed 16 Feb 2021.